About the project

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer's disease modifying drugs

We are aiming to:

• establish a strong network of academic-industrial partners with cutting-edge, unique proprietary technologies and knowledge​
• achieve scientific advancement in understanding the pathways of tau in neurodegeneration
• adopt a unique panel of techniques and considering important interaction partners of pathologic tau
• foster novel tools for neurodegeneration diagnostics and therapy

Project coordinator: CEITEC MU (Czech Republic)
Project partners: Axon Neuroscience (Slovak Republic) • Latvian Institute of Organic Synthesis • Royal College of Surgeons (Ireland) • University of Pittsburgh (USA) • Oregon State University (USA) • University Health Network (Canada)  • National University of Cuyo (Argentina)
Project duration: 48 months (01.01.2020 - 31.12.2023)
Project call: H2020-MSCA-RISE-2019
Total budget: 1 058 000 EUR

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 873127 – InterTAU.

This websiter reflects only the author's view and the Research Executive Agency (REA) is not responsible for any use that may be made of the information it contains.